Identification of Host Cell Proteins (HPCs) in Monoclonal Antibodies At Sub-ppm Levels Using the SYNAPT XS Mass Spectrometer

Catalin E. Doneanu, Alexandre Gomes, Brad J. Williams, Ying Qing Yu, Weibin Chen

Waters Corporation
Abstract

In this application note we describe a highly sensitive discovery HCP assay that can identify and quantify sub-ppm levels of HCPs from a highly purified monoclonal antibody.

Benefits

- A highly sensitive HCP discovery assay using the HDMS® data independent acquisition (DIA) mode identifies very low levels of HCPs (down to 100 ppb) from a highly purified monoclonal antibody
- When coupled with a literature reported sample preparation method, forty eight (48) HCPs were identified from the NIST mAb, demonstrating a considerable improvement in our ability to identify low abundance HCPs

Introduction

Residual host cell proteins (HCPs) are low-level (typically <100 ppm) process-related impurities, that might be present in protein biopharmaceuticals even after extensive purification. HCPs could produce unwanted immunogenic response in patients, reduce the efficacy or the stability of the drug or be responsible for drug degradation.¹ For these reasons, the regulatory agencies require that HCPs are identified and quantified prior to drug approval. The biopharmaceutical industry relies on ELISA assays for measuring the total HCP concentration expressed in ppm (or ng HCPs/mg biopharmaceutical). Mass spectrometry-based HCP analysis has emerged in recent years as a powerful alternative to ELISA²-⁶ because it provides more extensive (proteome-wide) HCP coverage and is able to identify and measure individual HCP levels.
Experimental Sample Preparation

A highly purified mAb (NIST mAb candidate reference LRM 8670) produced in a murine cell culture was ac...
**Column:**
ACQUITY PREMIER CSH C_{18} Column 1.7 µm, 2.1 x 150 mm (P/N: 186009462)

**Column temperature:** 60 °C

**Flow rate:** 50 µL/min

**Mobile phases:**
Solvent A: 0.1% FA in DI water
Solvent B: 0.1% FA in acetonitrile

**Injection volumes:** 50 µL

**Wash solvents:**
Purge solvent: 50% MeOH
Sample Manager wash solvent: 50% MeOH

**Gradient**

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Flow rate (mL/min)</th>
<th>Solvent A composition (%)</th>
<th>Solvent B composition (%)</th>
<th>Curve profile</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.00</td>
<td>0.2</td>
<td>100</td>
<td>0</td>
<td>Initial</td>
</tr>
<tr>
<td>2.00</td>
<td>0.2</td>
<td>100</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>2.10</td>
<td>0.05</td>
<td>100</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>25.00</td>
<td>0.05</td>
<td>90</td>
<td>10</td>
<td>6</td>
</tr>
<tr>
<td>82.00</td>
<td>0.05</td>
<td>80</td>
<td>20</td>
<td>6</td>
</tr>
<tr>
<td>112.00</td>
<td>0.05</td>
<td>70</td>
<td>30</td>
<td>6</td>
</tr>
<tr>
<td>113.00</td>
<td>0.4</td>
<td>70</td>
<td>30</td>
<td>6</td>
</tr>
<tr>
<td>120.00</td>
<td>0.4</td>
<td>50</td>
<td>50</td>
<td>6</td>
</tr>
<tr>
<td>122.00</td>
<td>0.4</td>
<td>50</td>
<td>50</td>
<td>6</td>
</tr>
<tr>
<td>123.00</td>
<td>0.4</td>
<td>100</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>124.00</td>
<td>0.4</td>
<td>100</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>134.00</td>
<td>0.4</td>
<td>100</td>
<td>0</td>
<td>6</td>
</tr>
</tbody>
</table>

**MS Conditions**

**MS System:** SYNAPT XS QTof Mass Spectrometer
Ionization mode: ESI+
Capillary voltage: 2.5 kV
Cone voltage: 40 V
Source offset: 4 V
Source temperature: 120 °C
Desolvation temperature: 300 °C
Cone gas flow: 35 L/h
Desolvation gas flow: 600 L/hr
Nebuliser gas Pressure: 7 bar
Data acquisition: HDMS$^E$ mode
Mass range ($m/z$): 50–2000
Scan rate: 1.0 sec
Low energy CE: 6 V
High energy CE ramp: Transfer Look-up Table (LUT) with CE in the range of 0–85 V
Data acquisition software: MassLynx 4.2 SCN 1009
Data processing software: Progenesis QI for Proteomics v4.2

Note: the CE values are correlated with the IMS drift times of peptide precursors (UDMS$^E$ acquisition)
Results and Discussion

The HCP impurities contained in the NIST mAb (100 mg/mL) have been previously characterized.\textsuperscript{2-6} Three laboratories using the same experimental setup - two dimensional microflow chromatography (high pH RP/low pH RP), coupled to a SYNAPT G2-Si Mass Spectrometer, collectively identified 35 HCPs, among which 14 HCPs were in common. This approach reached a detection limit of 1 ppm.\textsuperscript{2}

In recent years, several alternative sample preparation protocols have been introduced in order to increase the sensitivity of the LC-MS assay for identifying even lower levels of HCPs in mAb samples. These protocols either rely on the removal of the major drug species through mAb precipitation,\textsuperscript{4} or use low molecular-weight filters to remove the mAb and concentrate the HCPs\textsuperscript{5} or employ HILIC fractionation at the protein level to remove the major sample component and enrich the HCPs.\textsuperscript{6} Here we adapted a protocol introduced by Eli Lilly and Company\textsuperscript{4} to precipitate the NIST mAb, thus greatly minimizing the ion suppression and interference phenomena imposed by the more abundant NIST mAb peptides during the LC-MS analysis. Unlike the traditional digestion protocols using protein denaturation, reduction and alkylation before tryptic digestion, this approach relies on mAb resistance to trypsin digestion while in its native conformation. For this reason, HCPs non-covalently attached to the mAb are more easily digested by trypsin compared to the mAb, which stays mostly intact even during prolonged (overnight) digestion. According to this protocol, the sample is denatured, reduced, and alkylated after tryptic digestion, in order to precipitate and remove through centrifugation the major sample component. Our digestion protocol (detailed in the Experimental section) can be applied to other mAb products.

The digested sample was analyzed in triplicate using both MS\textsuperscript{E} and HDMS\textsuperscript{E} acquisition modes and the datasets were processed in Progenesis QI for Proteomics v4.2 for HCP identification and quantification. Only the HCPs identified in all three LC-MS replicates with 3 or more peptides per protein were reported. The MS\textsuperscript{E} acquisition was able to identify only 5 of the most abundant HCPs, reaching a detection limit of about 10 ppm (data not presented). In contrast with MS\textsuperscript{E}, the HDMS\textsuperscript{E} acquisition was able to identify significantly more HCPs - forty eight (48), improving the detection limit by 100 fold and reaching a detection level of 100 ppb. A detailed list of all the HCPs identified in all three replicates across 3 orders of magnitude is presented in Table 1. Compared to MS\textsuperscript{E}, the sensitivity of HDMS\textsuperscript{E} is greatly enhanced because in this acquisition mode the coeluting peptide precursors are separated by very fast (15-20 millisecond) ion mobility separations before fragmentation. As a result, the SYNAPT XS Mass Spectrometer provides cleaner MS/MS fragmentation spectra enabling many more HCP identifications. In addition, the collision energy (CE) used for peptide fragmentation is further optimized in the HDMS\textsuperscript{E} mode, by synchronizing the applied CE on the transfer cell.
with the IMS drift time of peptide precursors.
Table 1. Complete list of HCPs identified and quantified in the NIST mAb using the HDMS$^E$ assay developed on a SYNAPT XS Mass Spectrometer. Five spiked proteins (ENL, ClpB, ADH, PHO, and BSA) along with 48 HCPs were identified in all three replicate injections. Fourteen HCPs were identified at concentrations below 1 ppm, with the detection limit of the assay being at 100 ppb.
The list of HCPs identified in the HDMS$^E$ experiment was compared against the HCP identification reported in two previous publications$^{4,6}$ and the results are summarized in the Venn diagram shown in Figure 2. All three datasets contain a subset of 14 HCPs which was initially reported by our group.$^2$ In addition, each of the three datasets contains a unique subset of HCPs, identified only by a single laboratory: in our case 20 HCPs were only identified by the HDMS$^E$ acquisition on SYNAPT XS. Fourteen out of these 20 HCPs (highlighted in yellow in Table 1) were measured to have concentrations in the sub-ppm range (100–1000 ppb) demonstrating the excellent sensitivity of this assay. Clearly, while it is easier to identify the higher abundance HCPs contained in the NIST mAb sample, it appears that each different sample preparation procedure renders some unique very low level HCPs. This observation suggests the need to try different sample preparation methods in order to acquire a comprehensive HCP profile for this challenging mAb sample.
Figure 2. Venn diagram showing a comparison between the HCPs identified in the current study against the NIST mAb HCPs previously reported in the literature.

Conclusion

- A highly sensitive HCP discovery assay using HDMS\textsuperscript{E} data independent acquisition can identify very low levels of HCPs (sub-ppm) from a highly purified monoclonal antibody.
Forty eight (48) HCPs were identified from the NIST mAb, considerably improving our previous results reporting only 14 proteins identifications.

References


Featured Products

**ACQUITY UPLC I-Class PLUS System** [https://www.waters.com/10160596]

**SYNAPT XS High Resolution Mass Spectrometer** [https://www.waters.com/waters/nav.htm?cid=135020928]